EIRGEN PHARMA LTD. – Trademark Portfolio

Entity Type: 99

EIRGEN PHARMA LTD. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include ALPHAREN and RAYALDEE. The owner is based in WATERFORD.

WESTSIDE BUSINESS PARK, OLD KILMEADEN

ROAD

WATERFORD X91 YV67 , IE

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

EIRGEN PHARMA LTD.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

44
Medical Services (1 filing)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does EIRGEN PHARMA LTD. have?

EIRGEN PHARMA LTD. has 6 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned, 2 cancelled.

What trademark classes does EIRGEN PHARMA LTD. file in?

EIRGEN PHARMA LTD. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are EIRGEN PHARMA LTD.'s most well-known trademarks?

EIRGEN PHARMA LTD.'s registered trademark portfolio includes well-known marks such as ALPHAREN and RAYALDEE. These are among 3 currently registered trademarks in the portfolio.

What is EIRGEN PHARMA LTD.'s trademark registration success rate?

EIRGEN PHARMA LTD. has a 50% trademark registration rate, with 3 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.